Fresenius Kabi releases the biosimilar Tyenne (tocilizumab-aazg) in a subcutaneous formulation, which aims to increase the access to affordable and cost-effective options for use in the treatment of chronic autoimmune diseases. Tyenne is US FDA approved and is indicated for use in the treatment of chronic autoimmune diseases for certain indications of the reference product, Actemra (tocilizumab). It can be used in the treatment of inflammatory autoimmune diseases, including rheumatoid arthritis, giant cell arteritis, polyarticular juvenile idiopathic arthritis, and systemic juvenile idiopathic arthritis.